Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Pharmaceuticals Secures USD $1.9 Million Sales Contract for SmoothX 2% (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

PsyBio Therapeutics Corp V.PSYB.H

Alternate Symbol(s):  PSYBF

Healthcare Biotechnology
PsyBio Therapeutics Corp. is a Canada-based biotechnology company. The Company is focused on discovering, designing and developing psycho-focused therapeutics to improve mental and neurological conditions. It is focused on understanding the value of tryptamines and other related psycho-targeted molecules as therapeutic candidates to improve mental and neurological health. The Company is engaged in research and development for occurring psychoactive tryptamines, which is originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines, and combinations thereof. The Company utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon, which to develop precursors and analogs, both naturally and non-naturally occurring.


TSXV:PSYB.H - Post by User

PsyBio Therapeutics Corp > Time to Nibble at More Shares?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(70)
•••
Comment by Bookworm28on Mar 23, 2021 10:06pm
127 Views
Post# 32864027

RE:Time to Nibble at More Shares?

RE:Time to Nibble at More Shares?You're not the only one scratching their head PuerSimia. I agree with ValueValue123's comment about the stock being totally undervalued compared to their peers. Looking at the trading data, my current theory is selling by old timers from Leo Acquisitions who paid nothing for their shares, maybe some selling from the guys who participated in the IPO, and no buyers. They're in serious need of some promotion, and another a couple more press releases.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities